Pioneering The Next
Generation Of Targeted
Psychoative Medications
3 Primary Breakthroughs For The Treatment Of Mental Health Issues.
01.
Discovered an efficient, patent-pending bacterial biosynthesis process for tryptamine production.
02.
Developing a portfolio of tryptamine-derived, psychedelically inspired molecules.
03.
Demonstrated the entourage effect of certain tryptamines in a laboratory-controlled environment.
Paradigm Shift For Treating Mental Illness and Neurological Disorders
PsyBio Therapeutics is developing biosynthetic psychoactive compounds which offer a new paradigm of treatment to reverse the course of mental health issues.
PsyBio’s Objective Is to Develop Ground-Breaking Patient Treatments Based Upon Psychedelic Agents
PsyBio Therapeutics is creating a portfolio of unique, scientifically developed, psychoactive compounds as potential therapeutic agents for mental and neurologic health issues and developing an efficient, patent-pending bacterial biosynthesis process for tryptamine production with platform technology utilizing metabolic engineering and optimization techniques.
Psybio Has World Class Team Of Leaders and Experts
Experienced CEO with over 25 years in the Biotech Industry
Chief Medical Officer with Expanded Clinical Trial and Regulatory Experienc
Management is key to a successful biotechnology company in obtaining FDA approval for its leading therapeutic candidates.